Cancer has long been one of the banes of humanity. The disease has been known since antiquity, and it has been noted as a prominent killer the entirety of human history. Unfortunately, this record of mercilessly killing a good deal of those unlucky enough to develop this horrible disease continues to the present day.
Although modern medical techniques have gone a long way towards dramatically increasing the survivability of certain types of cancer, for others, the prognosis remains dismal. Cancer such as lung cancer, hepatocellular carcinoma, and pancreatic cancer have prognoses little better than those of patients suffering from the diseases 50 years ago.
It’s no surprise then, that some of medicine’s most harsh and powerful treatments have been directed towards fighting this killer disease. But for all of the gains that inventions like chemotherapy, radiation and surgical excision have conferred, they still have not been able to significantly improve the survivability of many different types of cancer.
That is why researchers have been constantly developing new means to fight this old disease. One of the most interesting forms of recent development in the cancer research space has been the advent of targeted cancer therapy. No one has been more important in the development of this exciting new class of drugs than Clay Siegall, CEO and founder of Seattle Genetics, the only biotech firm in the world dedicated solely to the research, development and production of targeted cancer therapy.
Dr. Clay Siegall and his firm have come up with one of the most innovative ways to treat cancer in recent history. By developing a class of drugs known as antibody drug conjugates, Dr. Siegall has created a thermonuclear option in the fight against cancer. Whereas chemotherapy, even as powerful as it is, has required that only small amounts be administered directly to the malignant tissue due to the extreme side effects that systemic release of chemotherapeutic agents carry with them, these new forms of cancer-fighting drugs will allow for massive dosages to be targeted directly at the malignancy. This will not only allow the patient to go through their courses of treatment under conditions of far greater comfort, but it will also allow for massively higher dosages to be concentrated at the site of the tumor.